Related Experiment Videos
Cardiovascular properties of the kallikrein-kinin system
Jagdish N Sharma1, Jyoti Sharma
1Department of Applied Therapeutics, Faculty of Pharmacy, Kuwait University, Safat. j.n.sharma@hsc.kuniv.edu.kw
Insights
The kallikrein-kinin system plays a role in cardiovascular diseases. Enhancing its activity through kallikrein gene delivery or kinin agonists shows promise for treating hypertension and related conditions.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- The kallikrein-kinin system (KKS) is present in vascular smooth muscle and the heart.
- Reduced KKS activity is linked to cardiovascular diseases like hypertension, cardiac failure, and myocardial infarction.
- Clinical and experimental data support the involvement of KKS in various cardiovascular pathologies.
Purpose of the Study:
- To explore the therapeutic potential of modulating the kallikrein-kinin system for cardiovascular and renal diseases.
- To investigate the benefits of kallikrein gene delivery in managing cardiovascular conditions.
- To assess the future prospects of kinin agonists as therapeutic agents.
Main Methods:
- Review of clinical and experimental models related to cardiovascular diseases.
- Analysis of observations linking KKS activity to disease induction.
- Evaluation of the effects of kallikrein gene delivery.
- Consideration of stable kinin agonists for therapeutic applications.
Main Results:
- Reduced activity of the local kallikrein-kinin system is implicated in cardiovascular disease development.
- Kallikrein gene delivery demonstrates a broad range of beneficial effects.
- Stable kinin agonists are emerging as potential future therapeutic agents.
Conclusions:
- Modulating the kallikrein-kinin system offers a promising therapeutic strategy for cardiovascular and renal disorders.
- Kallikrein gene therapy is a viable option for treating hypertension and related diseases.
- Future development of stable kinin agonists could provide new treatment avenues for cardiovascular and renal conditions.
Abstract:
All the components of the kallikrein-kinin system are located in the vascular smooth muscle as well as in the heart. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischaemia, myocardial infarction and left ventricular hypertrophy, have suggested that the reduced activity of the local kallikrein-kinin system may be instrumental in the induction of cardiovascular-related diseases. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension, and cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.